Chronic myelogenous leukemia: Update on biology and treatment

ONCOLOGY

Volumn 13, Issue 2, 1999, Pages 169-180

  Faderl, Stefan ^a   Kantarjian, Hagop M ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; BETA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARABINE DERIVATIVE; ERBSTATIN; FARNESYL TRANS TRANSFERASE; GENISTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERBIMYCIN A; HOMOHARRINGTONINE; HYDROXYUREA; INTERLEUKIN 4; LAVENDUSTIN A; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR; TYRPHOSTIN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG INDICATION; FLU LIKE SYNDROME; HUMAN; IMMUNOTHERAPY; LEUKEMOGENESIS; MYELOFIBROSIS; NEUROTOXICITY; PHILADELPHIA 1 CHROMOSOME; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE I, RECOMBINANT; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PHILADELPHIA CHROMOSOME; TREATMENT OUTCOME;

EID: 0032999728     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Kantarjian HM, Deisseroth A, Kurzrock R, et al: Chronic myelogenous leukemia: A concise update. Blood 82:691-703, 1993.
2. Cortes J, Talpaz M, Kantarjian H: Chronic myelogenous leukemia: A review. Am J Med 100:555-570, 1996.
3. Savage DG, Szydlo RM, Goldman JM: Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16-year period. Br J Haematol 96:111-116, 1997.
4. Kantarjian H, Dixon D, Keating MJ, et al: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441-1446, 1988.
5. Griffin JD, Todd III RF, Ritz J, et al: Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 61:85-91, 1983.
6. Kantarjian HM, Keating MJ, Talpaz M, et al: Chronic myelogenous leukemia in blast crisis: Analysis of 242 patients. Am J Med 83:445-454, 1987.
7. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497, 1960.
8. Kurzrock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990-998, 1988.
9. Kurzrock R, Shtalrid M, Romero P, et al: A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukemia. Nature 325:631-635, 1987.
10. Pane F, Frigeri F, Sindona M, et al: Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410-2414, 1996.
11. Melo JV, Myint H, Galton DAG, et al: P190 BCR-ABL chronic myeloid leukaemia: The missing link with chronic myelomonocytic leukaemia? Leukemia 8:208-211, 1994.
12. Pendergast AM, Quilliam LA, Cripe LD, et al: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185, 1993.
13. Daley GQ, Baltimore D: Transformation of an interleukin-3 dependent cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc Natl Acad Sci USA 85:9312-9316, 1988.
14. Daley GQ: Animal models on BCR/ ABL-induced leukemias. Leuk Lymphoma 11 (suppl 1):57-60, 1993.
15. Hochhaus A, Reiter A, Skladny H, et al: Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res 144:36-45, 1998.
16. Nolte M, Werner M, Ewig M, et al: Fluorescence in situ hybridization (FISH) is a reliable diagnostic tool for detection of the 9;22 translocation. Leuk Lymphoma 22:287-294, 1996.
17. Seong D, Kantarjian H, Ro J: Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 86:2343, 1995.
18. Dewald GW, Wyatt WA, Juneau AL, et al: Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 91:3357-3365, 1998.
19. Mitelman F: The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 11(suppl 1):11-15, 1993.
20. Kantarjian H, Keating M, Smith T, et al: Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88:1-8, 1990.
21. Sokal JE, Cox EB, Baccarani M: Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 63:789-799, 1998.
22. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 82:398-407, 1993.
23. Goldman JM, Szydlo R, Horowitz MM, et al: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235-2238, 1993.
24. Estrov Z, Kurzrock R, Talpaz M: Interferons. Basic Principles and Clinical Applications, 1st ed. Austin, Texas, R. G. Landes, 1993.
25. Talpaz M, McCredie KB, Mavligit GM, et al: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62:689-692, 1983.
26. Kantarjian HM, Smith TL, O'Brien SM, et al: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122:254-261, 1995.
27. Alimena G, Morra E, Lazzarino M, et al: Interferon alpha-2b as therapy for Ph′-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration. Blood 72:642-647, 1988.
28. Ozer H, George SL, Schiffer CA, et al: Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82:2975-2984, 1993.
29. Mahon F, Montastruc M, Faberes C, et al: Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon-α. Blood 84:3592-3594, 1994.
30. Ohnishi K, Ohno R, Tomonaga M, et al: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906-916, 1995.
31. Allan NC, Richards SM, Shepherd PCA, on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia: UK Medical Research Council randomized, multicentre trial of interferon-α n1 for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392-1397, 1995.
32. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825, 1994.
33. Hehlmann R, Heimpel H, Hasford J: Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia: The German CML Study Group. Blood 84:4064-4077, 1994.
34. Chronic Myeloid Leukemia Trialists' Collaborative Group: Interferon alfa versus chemotherapy for chronic myeloid leukemia: A metaanalysis of seven randomized trials. J Natl Cancer Inst 89:1616-1620, 1997.
35. Kantarjian HM, O'Brien S, Smith TL, et al: Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytosine arabinoside. J Clin Oncol 17:284-292, 1999.
36. Guilhot F, Chastang C, Michallet M, et al: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223-229, 1997.
37. Sacchi S, Kantarjian HM, Smith TL, et al: Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 16:882-889, 1998.
38. O'Brien S, Kantarjian H, Talpaz M: Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma 23:247-252, 1996.
39. Quesada JR, Talpaz M, Rios A, et al: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 4:234-243, 1986.
40. Enright H, Davies SM, DeFor T, et al: Relapse after non-T-cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood 88:714-720, 1996.
41. van Rhee F, Szydlo RM, Hermans J, et al: Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:553-560, 1997.
42. Clift RA, Storb R: Marrow transplantation for CML: The Seattle experience. Bone Marrow Transplant 17(suppl 3):S1-3, 1996.
43. Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954-1956, 1993.
44. Horowitz MM, Giralt S, Szydlo R, et al, for the International Bone Marrow Transplant Registry (IBMTR): Effects of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase (abstract). Exp Hematol 24:649, 1996.
45. Arcese W, Goldman JM, D'Arcangelo E, et al: Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 82:3211-3219, 1993.
46. Mrsíc M, Horowitz MM, Atkinson K, et al: Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 9:269-275, 1992.
47. Higano CS, Raskind WH, Singer JW: Use of a interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80:1437-1442, 1992.
48. Giralt SA, Kolb HJ: Donor lymphocyte infusions. Curr Opin Oncol 8:96-102, 1996.
49. Kantarjian HM, O'Brien SM, Anderline P, et al: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87:3069-3081, 1996.
50. Kantarjian HM, Talpaz M, O'Brien S, et al: Chronic myelogenous leukemia - progress at the M. D. Anderson Cancer Center over the past two decades and future directions: First Emil J. Freireich Award Lecture. Clin Cancer Res 3:2723-2733, 1997.
51. Shepherd PCA, Richards SM, Allan NC: Progress with interferon in CML - results of the MRC UK CML III Study. Bone Marrow Transplant 17 (suppl 3):S15-18, 1996.
52. Giralt SA, Kantarjian HM, Talpaz M, et al: Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055-1061, 1993.
53. Gratwohl A, Hermans J, Niederwieser D, et al: Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 12:509-516, 1993.
54. Gratwohl A, Hermans J, for the Working Party Chronic Leukemia of the European Group for Blood and Marrow Tranplantation (EBMT): Allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 17(suppl 3):S7-9, 1996.
55. McGlave P, Kollman C, Shu XO, et al: The first 1000 unrelated donor transplants for CML: lessons form the National Marrow Donor Program (NMDP) experience (abstract). Blood 88:483a, 1996.
56. Hansen JA, Gooley TA, Martin PJ, et al: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968, 1998.
57. Wilhelm M, Bueso-Ramos C, O'Brien S, et al: Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia 12:65-70, 1998.
58. McGlave P, Bartsch G, Anasetti C, et al: Unrelated donor marrow tranplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543-550, 1993.
59. Garnis AS, Haake R, McGlave P, et al: Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 11:834-838, 1993.
60. + cells present in autologous transplants of CML contribute to relapse after autologous bone marrow in CML. Blood 83:3068-3076, 1994.
61. McGlave PB, De Fabritiis P, Deisseroth A, et al: Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343:1486-1488, 1994.
62. Bhatia R, Forman SJ: Autologous transplantation for the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am 12:151-172, 1998.
63. O'Brien SM, Kantarjian H, Keating M, et al: Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86:3322-3326, 1995.
64. O'Brien S, Kantarjian H, Feldman E: Sequential homoharringtonine and interferon produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive chronic myelogenous leukemia (abstract). Proc Am Soc Clin Oncol 14:336, 1995.
65. Kantarjian H, O'Brien S, Keating M, et al: Homoharringtonine (HHT) and low-dose cytosine arabinoside (Ara-C) combination therapy has significant activity in patients (pts) with late phase Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) (abstract). Blood 88(suppl 1):578a, 1996.
66. Issa J-P, Baylin SG, Herman JG: DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11(suppl 1):7-11, 1997.
67. Kantarjian HM, O'Brien SM, Keating M, et al: Results of decitabine therapy in the accelerated and blastic phase of chronic myelogenous leukemia. Leukemia 11:1617-1620, 1997.
68. Senechal K, Sawyers CL: Signal transduction-based strategies for the treatment of CML. Mol Med Today 2:503-509, 1996.
69. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development. Science 267:1782-1788, 1995.
70. Jeha S, Luo XN, Beran M, et al: Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 56:1445-1450, 1996.
71. Falkenburg JHF, Smit WM, Willemze R: Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol Rev 157:223-230, 1997.
72. Choudhoury A, Gajewski JL, Liang JC, et al: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89:1133-1142, 1997.
73. Sokal JE, Baccarani M, Russo D, et al: Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49-61, 1988.
74. Ansari H, Hasford J, Hehlmann R, and the German CML Study Group: Fallacies of the intention-to-treat analysis (abstract). J Mol Med 75:B243, 1997.
75. Kantarjian HM, Giles FJ, O'Brien SM, et al: Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 12:31-80, 1998.